The TGA, or Therapeutic Goods Administration, is Australia’s regulatory authority for medicines, medical devices, and other health products. It sits within the Australian Government Department of Health and is responsible for ensuring that therapeutic goods sold in Australia are safe, effective, and meet quality standards. Think of it as Australia’s equivalent of the FDA in the United States or the EMA in Europe.
What the TGA Regulates
The TGA oversees a broad range of health products. Medicines, both prescription and over-the-counter, fall under its authority. So do medical devices, which range from simple bandages to complex implants and diagnostic equipment. Biologicals, products made from or containing human cells and tissues, are also regulated. Even some products you might not immediately think of, like sterilants, disinfectants, tampons, and menstrual cups, come under TGA oversight.
Equally important is what the TGA does not regulate. Cosmetics, food, veterinary medicines, chemicals, health insurance, and healthcare professionals all fall outside its scope. Those are handled by separate Australian agencies. So if a product is purely cosmetic with no therapeutic claim, the TGA has no jurisdiction over it. But the moment a product claims to treat, prevent, or diagnose a health condition, it enters the TGA’s territory.
How Products Get Approved
Before a therapeutic good can be legally sold in Australia, it generally needs to be entered on the Australian Register of Therapeutic Goods (ARTG). The ARTG is the official database of all approved therapeutic goods in the country, and it’s publicly searchable. If a product isn’t on the register and doesn’t qualify for a specific exemption, it cannot be legally supplied.
The level of scrutiny a product receives depends on its risk. Lower-risk products like most vitamins and supplements go through a lighter evaluation process, while prescription medicines and higher-risk devices face more rigorous assessment of their safety, efficacy, and quality before they can be added to the register.
Safety Monitoring After Approval
The TGA’s role doesn’t end once a product hits the market. It runs an ongoing safety monitoring system, known as pharmacovigilance, to detect problems that might not have appeared during clinical trials. Companies that sponsor approved medicines are legally required to report serious adverse reactions, notify the TGA of significant safety issues, and maintain detailed safety records.
New prescription medicines in Australia carry a Black Triangle symbol on their product information documents. This serves as a visual reminder for both healthcare professionals and patients to report any side effects, since newer medicines have less real-world safety data. The TGA also issues public safety alerts and updates when new risks are identified with any therapeutic good.
Enforcement Powers
The TGA has significant teeth when it comes to enforcement. Its powers range from issuing formal warning letters for minor issues to pursuing criminal penalties for serious violations. If a product is found to be non-compliant, the TGA can suspend it from the ARTG, which immediately blocks its import, export, manufacture, and supply across Australia. In more serious cases, a product can be permanently cancelled from the register, seized from the market, tested in TGA laboratories, and destroyed.
The agency can also pursue civil penalties through the Federal Court. Maximum civil penalties reach 5,000 penalty units for individuals and 50,000 for corporations. It can seek court injunctions to force companies into compliance or restrain them from further violations. For companies that agree to fix problems voluntarily, the TGA uses enforceable undertakings, legally binding agreements that carry court consequences if broken.
When a safety problem is found with a product already on shelves, the TGA can trigger market actions: formal recalls, product alerts, or product corrections that pull unsafe goods from the supply chain.
How the TGA Is Funded
Unlike some government agencies that run entirely on taxpayer money, the TGA operates largely on a cost-recovery model. In 2025-26, roughly 73% of its funding comes from fees and charges paid by the companies whose products it regulates. These fees cover application evaluations, annual registration charges, and other regulatory services. The remaining funding comes from government appropriations.
The Legal Foundation
The TGA draws its authority from the Therapeutic Goods Act 1989, which established a national system of controls for the quality, safety, efficacy, and timely availability of therapeutic goods used in or exported from Australia. The Act defines therapeutic goods broadly: products used for preventing, diagnosing, curing, or treating disease; products that modify how the body works; contraceptives; and pregnancy tests all fall within the definition.
International Cooperation
The TGA doesn’t work in isolation. It participates in the Access Consortium alongside regulators from Canada, Singapore, Switzerland, and the United Kingdom, sharing assessments to reduce duplication and speed up approvals. Through Project Orbis, it collaborates with international partners on reviews of promising cancer treatments. It also works with the International Coalition of Medicines Regulatory Authorities (which includes over 40 agencies worldwide), the International Medical Device Regulators Forum, and the World Health Organization.
In practice, this means the TGA often relies on assessments from comparable overseas regulators to support its own decisions. This work-sharing approach helps a relatively small agency keep pace with the volume of new medicines and devices entering the global market, while still applying its own standards for the Australian context.